Johnson & Johnson

Is Johnson & Johnson publicly traded?
Yes, Johnson & Johnson is publicly traded on the New York Stock Exchange under the ticker symbol JNJ. The company has been publicly traded since 1944 and is one of the most widely held healthcare stocks globally, included in major stock market indices including the Dow Jones Industrial Average.

What were Johnson & Johnson's FY2025 financial results?
J&J reported full-year 2025 sales of $94.2 billion, up 6.0% year-over-year, with net earnings of $26.8 billion and adjusted EPS of $10.79. Q4 2025 sales grew 9.1% to $24.6 billion. The company generated approximately $19.7 billion in free cash flow and increased its dividend for the 63rd consecutive year.

Who is Johnson & Johnson's CEO?
Joaquin Duato serves as Chairman and CEO of Johnson & Johnson. He became CEO in 2022 and described 2025 as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history. Duato has focused J&J on six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.

What is Johnson & Johnson's 2026 outlook?
J&J issued 2026 guidance of $100.5 billion in estimated reported sales (6.7% growth at midpoint) and adjusted EPS of $11.53 (6.9% growth at midpoint). This guidance accounts for approximately $500 million in expected tariff impacts and a drug pricing agreement with the Trump administration.

What are Johnson & Johnson's main business segments?
J&J operates through two segments: Innovative Medicine (pharmaceuticals), which generated $60.4 billion in 2025 sales, and MedTech (medical devices), which contributed $33.8 billion. The company previously had a third Consumer Health segment, which was spun off as Kenvue in 2023.

What happened to Johnson & Johnson's consumer brands?
In 2023, J&J completed the spin-off of its consumer health business as Kenvue, which included Tylenol, Band-Aid, Johnson's Baby, Neutrogena, Aveeno, Listerine, and other consumer brands. Kenvue was fully separated in August 2023 via an IPO and exchange offer. These brands remain associated with J&J in public recognition.

What medical innovations did J&J achieve in 2025?
J&J secured FDA approval of CAPLYTA for major depressive disorder, approval of RYBREVANT FASPRO plus LAZCLUZE for non-small cell lung cancer, and reported landmark data for TECVAYLI plus DARZALEX FASPRO for multiple myeloma. The company also acquired Halda Therapeutics and submitted the OTTAVA Robotic Surgical System for regulatory review.

What is the talc litigation status?
J&J faces thousands of lawsuits alleging its talc-based baby powder caused ovarian cancer and mesothelioma. In October 2025, a California jury awarded $966 million to a mesothelioma victim's family. In March 2025, a bankruptcy judge rejected J&J's proposed $8 billion settlement for ovarian cancer claims. The litigation remains ongoing.

Johnson & Johnson was founded in 1886 by three brothers: Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson. The company began with 14 employees producing sterile surgical dressings in a former wallpaper factory in New Brunswick, New Jersey. Robert Wood Johnson's vision was to provide sterile surgical supplies to help prevent infections in medical procedures.

The company's first major innovation was the introduction of sterile surgical dressings and sutures, which reduced surgical infection rates. Johnson's Baby Powder was introduced in 1893 and became one of the company's most successful products. The Band-Aid adhesive bandage was introduced in 1920 and became a household name.

The company entered the pharmaceutical business in the 1930s. In 1943, Robert Wood Johnson wrote the company's credo, which emphasizes responsibility to customers first, then employees, communities, and shareholders. This credo continues to guide J&J's business decisions.

The post-World War II period saw accelerated growth and diversification into medical devices and diagnostics. Major acquisitions included Neutrogena (1994), Aveeno (1999), and Pfizer Consumer Healthcare (2006), which expanded J&J's over-the-counter medication portfolio.

In 2021, Johnson & Johnson completed the spin-off of its consumer health business as Kenvue, which included brands like Tylenol, Band-Aid, Johnson's Baby, Neutrogena, and Aveeno. However, J&J retained ownership of these brands within its Innovative Medicine and MedTech segments through licensing arrangements, and many of these brands remain associated with J&J in the public consciousness. Kenvue was fully separated in August 2023 via an IPO and exchange offer.

Under CEO Joaquin Duato, who became CEO in 2022, J&J has focused on six key therapeutic areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. Duato described 2025 as a "catapult year" fueled by the strongest portfolio and pipeline in the company's history.

In 2025, J&J invested more than $32 billion in research, development, and strategic acquisitions, including Intra-Cellular Therapies (CAPLYTA) and Halda Therapeutics, along with 40 other collaborations, partnerships, and licenses. The company also initiated billions of dollars in new U.S. manufacturing facilities as part of a plan to invest $55 billion in the U.S. over four years.

Johnson & Johnson has committed to carbon neutrality in global operations (Scope 1 and 2) by 2030 and net-zero emissions across its entire value chain by 2045. The company has set science-based targets to reduce Scope 1 and 2 greenhouse gas emissions by 44% by 2030 and has committed to 100% renewable electricity for its operations.

The company's credo, written in 1943, continues to guide its ethical business practices, emphasizing responsibility to customers first, then employees, communities, and shareholders. J&J maintains comprehensive compliance programs covering pharmaceutical regulations, medical device standards, and consumer product safety.

J&J supports healthcare access in underserved communities through the Johnson & Johnson Foundation, product donations, medical professional training, and health system strengthening programs.

• Fortune World's Most Admired Companies (2025 and 2026): Ranked among the world's most admired companies in the pharmaceuticals category for the 17th consecutive year
• Fortune America's Most Innovative Companies (2025): Named for breakthrough medical innovations and healthcare solutions
• Dow Jones Sustainability Index: Consistent inclusion for ESG performance among global pharmaceutical companies
• CDP Climate Leadership: Recognition for climate disclosure and environmental performance
• Science Based Targets Initiative: Recognition for validated emissions reduction targets

The talc powder litigation represents J&J's most significant legal challenge. The company faces thousands of lawsuits alleging that its talc-based baby powder and cosmetic products caused ovarian cancer and mesothelioma. In October 2025, a California jury awarded $966 million to the family of a woman who died from mesothelioma after using J&J talc products. In March 2025, a bankruptcy judge rejected the company's proposed $8 billion settlement for ovarian cancer claims. J&J attempted to resolve talc claims through bankruptcy proceedings using its LTL Management subsidiary, but this strategy faced legal challenges from government agencies and claimants.

J&J has also faced scrutiny regarding its role in the opioid crisis. The company settled opioid-related lawsuits with multiple states and local governments, paying substantial sums to address claims that its opioid marketing and distribution practices contributed to the addiction epidemic.

Drug pricing controversies have drawn regulatory attention regarding the cost of specialty medications and biologic drugs. J&J has faced criticism from lawmakers and patient advocacy groups about pricing practices, particularly for oncology treatments. The company reached a drug pricing agreement with the Trump administration in 2025, the details of which have not been fully disclosed but are estimated to cost hundreds of millions of dollars.